Phase-2 study of Tarceva [erlotinib] in patients with recurrent phospho-Akt negative glioblastoma multiforme and gliosarcoma.
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 Jan 2013 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 15 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.